Roche has provided a community update on the SUNFISH trial of Evrysdi (risdiplam) showing continued long-term efficacy and safety in SMA Types 2 and 3:
- “Data from pivotal SUNFISH study showed increases in motor function observed during the first year were maintained through the fourth year, while the overall rate of adverse events continued to decrease.
- Data confirm long-term efficacy and safety profile of Evrysdi in a broad range of people with Type 2 and non‑ambulant Type 3 SMA.
- More than 8,500 people – from newborns to the over 60s – have been treated with Evrysdi, which is now approved in more than 90 countries worldwide.”
